You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification Name OspA lipoprotein Accession Number DB00045 (BIOD00054, BTD00054) Type Biotech Groups Approved, Withdrawn Description
Vaccine against Lyme disease that contains lipoprotein OspA, an outer surface protein of Borrelia burgdorferi sensu stricto ZS7, as expressed by Escherichia coli. Lipoprotein OspA is a single polypeptide chain of 257 amino acids with lipids covalently bonded to the N terminus. It is conjugated with alum (aluminum hydroxide) as an adjuvant.
Protein structure Protein chemical formula C 1198H 2012N 322O 422S 2 Protein average weight 27743.1 Da Sequences > OspA lipoprotein
TITVQNYDSAGTKLEGSAAEIKKLDELKNALR Download FASTA Format Synonyms
Outer surface protein A precursor External Identifiers Not Available Prescription Products Not Available Generic Prescription Products Not Available Over the Counter Products Not Available International Brands
Name Company LYMErix SmithKline Beecham Brand mixtures Not Available Salts Not Available Categories UNII Not Available CAS number Not Available Taxonomy Description Not Available Kingdom Organic Compounds Super Class Organic Acids Class Carboxylic Acids and Derivatives Sub Class Amino Acids, Peptides, and Analogues Direct Parent Peptides Alternative Parents Not Available Substituents Not Available Molecular Framework Not Available External Descriptors Not Available Pharmacology Indication For prophylactic treatment of Lyme Disease Pharmacodynamics OspA lipoprotein is a single polypeptide chain of 270 amino acids. It is a vaccination used to prevent Lyme Disease. Mechanism of action OspA lipoprotein, an outer surface protein of the bacteria Borrelia burgdorferi sensu stricto ZS7, is used to stimulate the production of specific antibodies against B. burgdorferi. It is used as a vaccination against Lyme Disease, a disease carried by ticks. Absorption Not Available Volume of distribution Not Available Protein binding Not Available Metabolism Not Available Route of elimination Not Available Half life 1.2 hours (mammalian reticulocytes, in vitro). Clearance Not Available Toxicity Not Available Affected organisms Pathways Not Available SNP Mediated Effects Not Available SNP Mediated Adverse Drug Reactions Not Available Pharmacoeconomics Manufacturers Not Available Packagers Not Available Dosage forms Not Available Prices Not Available Patents Not Available Properties State Liquid Experimental Properties
Property Value Source hydrophobicity -0.652 Not Available isoelectric point 6.72 Not Available References Synthesis Reference Not Available General References Not Available External Links ATC Codes Not Available AHFS Codes Not Available PDB Entries FDA label Not Available MSDS Not Available Interactions Drug Interactions Not Available Food Interactions Not Available Targets
Welty DM, Snyder DS: Internalization of OspA in rsCD14 complex and aggregated forms. Mol Microbiol. 2003 Nov;50(3):835-43.
comments powered by Disqus. comments powered by
Drug created on June 13, 2005 07:24 / Updated on January 27, 2014 13:29